LivaNova PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIVN research report →
Range $85 – $120
Price Chart
About the company
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems.
- CEO
- Vladimir A. Makatsaria
- IPO
- 2015
- Employees
- 3,300
- HQ
- Gloucester, GL, GB
Get TickerSpark's AI analysis on LIVN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.00B
- P/E
- 25.34
- Fwd P/E
- 20.46
- PEG
- 0.09
- P/S
- 3.32
- P/B
- 3.64
- EV/EBITDA
- 22.63
- Div Yield
- 0.00%
- Gross Margin
- 67.91%
- Op Margin
- 11.46%
- Net Margin
- 13.01%
- ROE
- 15.35%
- ROIC
- 8.74%
Latest fiscal year · YoY change
- Revenue
- $1.39B+10.7%
- Gross Profit
- $939.90M+7.9%
- Op Income
- $199.40M
- Net Income
- $-242,500,000-483.5%
- EPS
- $-4.45-480.3%
- OCF Growth
- +38.9%
- FCF Growth
- +27.4%
- 52W High
- $99.38
- 52W Low
- $56.44
- 50D MA
- $81.60
- 200D MA
- $74.85
- Beta
- 0.92
- RSI (14)
- 59
- Avg Volume
- 689.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
LivaNova beat with 10% revenue growth, raised full-year guidance, and highlighted stronger cardiopulmonary and epilepsy momentum alongside advancing its OSA launch plans.· November 4, 2026
- Q3 revenue was $393 million, up 10% year over year, with adjusted diluted EPS of $1.23 versus $1.11 last year.
- Cardiopulmonary revenue was $225 million, up 11%, driven by double-digit growth in Europe and the US and strong oxygenator demand.
- Epilepsy revenue rose 11% year over year, helped by better volume, favorable realized price, improved reimbursement, and clinical evidence.
- Full-year 2026 guidance was raised: revenue growth to 9% to 10%, epilepsy growth to 8% to 9%, and cardiopulmonary growth to 10.5% to 11.5%.
- Management said the new oxygenator line is live, OSA remains on track for a limited 2027 launch, and the new CPT codes for pHGNS are expected to take effect on January 1, 2028.
Third quarter 2026 revenue was $393 million, up 10% versus the prior year. Cardiopulmonary revenue was $225 million, up 11%, and epilepsy revenue increased 11% year over year. Adjusted gross margin was 69%, flat with last year; adjusted operating income was $92 million versus $80 million; and adjusted diluted EPS was $1.23 compared with $1.11. For the full year, LivaNova now expects revenue growth of 9% to 10% on a constant-currency basis, adjusted diluted EPS of $4.40 to $4.50, adjusted operating margin of 20% to 21%, and adjusted free cash flow of $140 million to $160 million. Management also said foreign exchange should be a tailwind of about 1%, tariffs should have a net impact of less than $5 million on adjusted operating income, and capital spending should be $135 million.
Vladimir A. Makatsaria framed the quarter as another period of broad-based double-digit growth, citing commercial execution and strong demand across cardiopulmonary and epilepsy. He emphasized that LivaNova is using its core businesses to fund disciplined investment in future growth, especially obstructive sleep apnea, which he described as an attractive high-growth, high-margin market. His tone was confident and strategic, repeatedly pointing to differentiated technology, clinical evidence, and the company’s ability to win in underpenetrated markets.
Alex Shvartsburg said the quarter showed solid execution and an improved business outlook. He cited adjusted gross margin of 69%, adjusted SG&A of $136 million, adjusted R&D of $45 million, adjusted operating income of $92 million, and adjusted diluted EPS of $1.23. On cash and capital allocation, he noted cash of $563 million and total debt of $299 million at September 30, with both lower after an early repayment of $98 million of the term facility; adjusted free cash flow was $56 million for the quarter, and year-to-date capital spend was $77 million versus $49 million last year. He also said guidance still assumes about $135 million of capital spending and maintains the company’s margin framework despite higher investment in OSA and capacity expansion.
Analysts focused on cardiopulmonary growth durability, the new oxygenator manufacturing line, OSA commercialization timing, epilepsy pricing, and the outlook for margins and reimbursement. Management said the new oxygenator line is live but will not materially affect results until next year, and expects double-digit output improvement in 2027 versus 2026. On OSA, management reiterated a limited 2027 launch, more meaningful commercial investment in 2028, and said the new AMA category 1 codes are expected to begin January 1, 2028; they also said reimbursement uncertainty is temporary and highlighted the absence of a CCC contraindication. For epilepsy, management said realized price remains stronger because of lower discounting and better reimbursement, with additional premium-pricing potential for the next-gen product.
The call showed momentum in both current businesses, with double-digit revenue growth and a raised full-year outlook. Management also pointed to supply-chain and manufacturing upgrades, improving reimbursement, and supportive clinical evidence as drivers that can extend growth into 2027 and beyond.
Near-term guidance still implies heavier fourth-quarter investment, especially for OSA development and cardiopulmonary capacity expansion, and management said the new oxygenator line will not meaningfully benefit results until next year. The OSA opportunity also still depends on regulatory timing, payer clarity, and market adoption, while the company acknowledged ongoing reimbursement uncertainty in the HGNS market until new codes take effect in 2028.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 55.09M
- Float Shares
- 54.83M
of shares held by institutions
313 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 7.74M | ▲ 174.32K |
| Primecap Management Co | 4.19M | ▲ 18.78K |
| Fmr LLC | 3.98M | ▲ 829.58K |
| Invesco Ltd. | 2.91M | ▲ 676.70K |
| Hood River Capital Management LLC | 2.57M | ▲ 2.76K |
| Vanguard Group Inc | 2.33M | ▲ 34.81K |
| State Street Corp | 2.17M | ▲ 294 |
| Aqr Capital Management LLC | 2.03M | ▼ 326.98K |
| American Century Companies Inc | 2.01M | ▼ 2.18K |
| Dimensional Fund Advisors LP | 1.89M | ▲ 46.81K |
| Artisan Partners Limited Partnership | 1.80M | ▼ 427.73K |
| Geode Capital Management, LLC | 1.76M | ▲ 9.10K |
Held by 459 ETFs
Biggest fund positions in LIVN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Shvartsburg Alex | sell | 2,500 |
| Sep 15, 26 | Liddy Anne M. | other | 6,291 |
| Sep 10, 26 | Bianchi Francesco | sell | 3,500 |
| Sep 4, 26 | Story Brooke | sell | 2,300 |
| Aug 31, 26 | Bianchi Francesco | sell | 1,650 |
| Aug 31, 26 | Liddy Anne M. | other | 0 |
| Aug 11, 26 | Tezel Ahmet | other | 12,692 |
| Aug 11, 26 | Tezel Ahmet | other | 12,692 |
| Aug 11, 26 | Tezel Ahmet | sell | 8,589 |
| Aug 11, 26 | Tezel Ahmet | other | 1,428 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LIVN coverage
Recent articles, reports, and earnings notes.
No research on LIVN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LIVN report →LivaNova: Paying Off The Last Legacy Bill Just As The Sleep Apnea Market Opens Up
seekingalpha.com · Nov 12
LivaNova PLC (LIVN) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 9
LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
LivaNova Q3 Earnings Call Highlights
marketbeat.com · Nov 4
LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com · Nov 4
LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Nov 4
LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
businesswire.com · Nov 4
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
businesswire.com · Oct 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.